Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge

Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge

Parkinson’s disease (PD) is a neurodegenerative disease with significant unmet medical needs. The current dopamine-centered treatments aim to restore motor functions of patients without slowing the disease progression. Long-term usage of these drugs is associated with diminished efficacy, motor fluc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS chemical neuroscience 2019-02, Vol.10 (2), p.783-791
Hauptverfasser: Zheng, Jiyue, Zhang, Xiaohu, Zhen, Xuechu
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 791
container_issue 2
container_start_page 783
container_title ACS chemical neuroscience
container_volume 10
creator Zheng, Jiyue
Zhang, Xiaohu
Zhen, Xuechu
description Parkinson’s disease (PD) is a neurodegenerative disease with significant unmet medical needs. The current dopamine-centered treatments aim to restore motor functions of patients without slowing the disease progression. Long-term usage of these drugs is associated with diminished efficacy, motor fluctuation, and dyskinesia. Furthermore, the nonmotor features associated with PD such as sleep disorder, pain, and psychiatric symptoms are poorly addressed by the dopaminergic treatments. Adenosine receptor A2A antagonists have emerged as potential treatment for PD in the past decade. Here we summarize the recent work (2015–2018) on adenosine receptor A2A antagonists and discuss the challenge and opportunity for the treatment of PD.
doi_str_mv 10.1021/acschemneuro.8b00313
format Article
fullrecord <record><control><sourceid>proquest_acs_j</sourceid><recordid>TN_cdi_proquest_miscellaneous_2102322953</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2102322953</sourcerecordid><originalsourceid>FETCH-LOGICAL-a210t-5aba9718784b34ad856ca80548e84a480391e0dda738e90d50774029c51d1f423</originalsourceid><addsrcrecordid>eNpNkEtOwzAQhi0EEqVwAxZesgn4lcZmF7W8pEog1K6jaTxpU1I7xC4bNlyD63ESglqkrmZG-uaf0UfIJWfXnAl-A2UoV7hxuO38tV4wJrk8IgNulE4ybuTxQX9KzkJYMzYyTI8G5HOCH9j4doMuUl_R3KLzoXZIc5HTVyyxjb6juYuw9K4OMdCqn-MK6axDiP97L9C91S549_P1HeikDggBb-kuokfmrYWIFJyl4xU0DbolnpOTCpqAF_s6JPP7u9n4MZk-PzyN82kCgrOYpLAAk3GdabWQCqxORyVoliqNWoHSTBqOzFrIpEbDbMqyTDFhypRbXikhh-Rql9t2_n2LIRabOpTYNODQb0PRXxFSCJPKHmU7tFdarP22c_1jBWfFn-fi0HOx9yx_AYypdW8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2102322953</pqid></control><display><type>article</type><title>Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge</title><source>ACS Publications</source><creator>Zheng, Jiyue ; Zhang, Xiaohu ; Zhen, Xuechu</creator><creatorcontrib>Zheng, Jiyue ; Zhang, Xiaohu ; Zhen, Xuechu</creatorcontrib><description>Parkinson’s disease (PD) is a neurodegenerative disease with significant unmet medical needs. The current dopamine-centered treatments aim to restore motor functions of patients without slowing the disease progression. Long-term usage of these drugs is associated with diminished efficacy, motor fluctuation, and dyskinesia. Furthermore, the nonmotor features associated with PD such as sleep disorder, pain, and psychiatric symptoms are poorly addressed by the dopaminergic treatments. Adenosine receptor A2A antagonists have emerged as potential treatment for PD in the past decade. Here we summarize the recent work (2015–2018) on adenosine receptor A2A antagonists and discuss the challenge and opportunity for the treatment of PD.</description><identifier>ISSN: 1948-7193</identifier><identifier>EISSN: 1948-7193</identifier><identifier>DOI: 10.1021/acschemneuro.8b00313</identifier><language>eng</language><publisher>American Chemical Society</publisher><ispartof>ACS chemical neuroscience, 2019-02, Vol.10 (2), p.783-791</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-0579-1636</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acschemneuro.8b00313$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acschemneuro.8b00313$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,27053,27901,27902,56713,56763</link.rule.ids></links><search><creatorcontrib>Zheng, Jiyue</creatorcontrib><creatorcontrib>Zhang, Xiaohu</creatorcontrib><creatorcontrib>Zhen, Xuechu</creatorcontrib><title>Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge</title><title>ACS chemical neuroscience</title><addtitle>ACS Chem. Neurosci</addtitle><description>Parkinson’s disease (PD) is a neurodegenerative disease with significant unmet medical needs. The current dopamine-centered treatments aim to restore motor functions of patients without slowing the disease progression. Long-term usage of these drugs is associated with diminished efficacy, motor fluctuation, and dyskinesia. Furthermore, the nonmotor features associated with PD such as sleep disorder, pain, and psychiatric symptoms are poorly addressed by the dopaminergic treatments. Adenosine receptor A2A antagonists have emerged as potential treatment for PD in the past decade. Here we summarize the recent work (2015–2018) on adenosine receptor A2A antagonists and discuss the challenge and opportunity for the treatment of PD.</description><issn>1948-7193</issn><issn>1948-7193</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpNkEtOwzAQhi0EEqVwAxZesgn4lcZmF7W8pEog1K6jaTxpU1I7xC4bNlyD63ESglqkrmZG-uaf0UfIJWfXnAl-A2UoV7hxuO38tV4wJrk8IgNulE4ybuTxQX9KzkJYMzYyTI8G5HOCH9j4doMuUl_R3KLzoXZIc5HTVyyxjb6juYuw9K4OMdCqn-MK6axDiP97L9C91S549_P1HeikDggBb-kuokfmrYWIFJyl4xU0DbolnpOTCpqAF_s6JPP7u9n4MZk-PzyN82kCgrOYpLAAk3GdabWQCqxORyVoliqNWoHSTBqOzFrIpEbDbMqyTDFhypRbXikhh-Rql9t2_n2LIRabOpTYNODQb0PRXxFSCJPKHmU7tFdarP22c_1jBWfFn-fi0HOx9yx_AYypdW8</recordid><startdate>20190220</startdate><enddate>20190220</enddate><creator>Zheng, Jiyue</creator><creator>Zhang, Xiaohu</creator><creator>Zhen, Xuechu</creator><general>American Chemical Society</general><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0579-1636</orcidid></search><sort><creationdate>20190220</creationdate><title>Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge</title><author>Zheng, Jiyue ; Zhang, Xiaohu ; Zhen, Xuechu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a210t-5aba9718784b34ad856ca80548e84a480391e0dda738e90d50774029c51d1f423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Jiyue</creatorcontrib><creatorcontrib>Zhang, Xiaohu</creatorcontrib><creatorcontrib>Zhen, Xuechu</creatorcontrib><collection>MEDLINE - Academic</collection><jtitle>ACS chemical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Jiyue</au><au>Zhang, Xiaohu</au><au>Zhen, Xuechu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge</atitle><jtitle>ACS chemical neuroscience</jtitle><addtitle>ACS Chem. Neurosci</addtitle><date>2019-02-20</date><risdate>2019</risdate><volume>10</volume><issue>2</issue><spage>783</spage><epage>791</epage><pages>783-791</pages><issn>1948-7193</issn><eissn>1948-7193</eissn><abstract>Parkinson’s disease (PD) is a neurodegenerative disease with significant unmet medical needs. The current dopamine-centered treatments aim to restore motor functions of patients without slowing the disease progression. Long-term usage of these drugs is associated with diminished efficacy, motor fluctuation, and dyskinesia. Furthermore, the nonmotor features associated with PD such as sleep disorder, pain, and psychiatric symptoms are poorly addressed by the dopaminergic treatments. Adenosine receptor A2A antagonists have emerged as potential treatment for PD in the past decade. Here we summarize the recent work (2015–2018) on adenosine receptor A2A antagonists and discuss the challenge and opportunity for the treatment of PD.</abstract><pub>American Chemical Society</pub><doi>10.1021/acschemneuro.8b00313</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-0579-1636</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1948-7193
ispartof ACS chemical neuroscience, 2019-02, Vol.10 (2), p.783-791
issn 1948-7193
1948-7193
language eng
recordid cdi_proquest_miscellaneous_2102322953
source ACS Publications
title Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T02%3A47%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_acs_j&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Adenosine%20A2A%20Receptor%20Antagonists%20for%20the%20Treatment%20of%20Parkinson%E2%80%99s%20Disease:%20A%20Recent%20Update%20and%20Challenge&rft.jtitle=ACS%20chemical%20neuroscience&rft.au=Zheng,%20Jiyue&rft.date=2019-02-20&rft.volume=10&rft.issue=2&rft.spage=783&rft.epage=791&rft.pages=783-791&rft.issn=1948-7193&rft.eissn=1948-7193&rft_id=info:doi/10.1021/acschemneuro.8b00313&rft_dat=%3Cproquest_acs_j%3E2102322953%3C/proquest_acs_j%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2102322953&rft_id=info:pmid/&rfr_iscdi=true